Weight loss outcomes : Semaglutide at the doses used for weight management (Wegovy, 2.4 mg weekly) has produced average weight loss of 15-17% of body weight over 68 weeks in clinical trials (STEP program)
"My hypothesis, with anecdotal evidence, is when someone who hasn't been fit becomes fit, starts becoming fit, they change their life to make sure they're protecting and truly being fit," Siegel said
Two-Month Contractual Commitment Binding Agreement: Once medication has been shipped, a binding two-month contract is established
Beyond the GI tract, semaglutide has been associated with fatigue, dizziness, headaches, and changes in taste perception
10.1016/j.deman.2022.100115 8 CollinsL.CostelloR
They verify that temperature-sensitive compounds are transported safely and documented properly